Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab for Lichen Planopilaris
NCT07396168Phase 4Recruiting
- Sponsor
- The Skin Center Dermatology Group
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of nemolizumab in lichen planopilaris (LPP), sponsored by The Skin Center Dermatology Group. Started Feb 2026; status: recruiting.
02
Drugs
nemolizumab
03
Conditions
lichen planopilaris (LPP)
Beyond the preview
Go deeper on NCT07396168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396168.